Document:

EX-10.21

 Exhibit 10.21 
 REIMBURSEMENT AGREEMENT 
 This REIMBURSEMENT AGREEMENT
(this “Agreement”), dated as of July 11, 2013, is entered into by and among Biocept, Inc., a California corporation (“Borrower”), The Reiss Family Survivor’s Trust UDT Dated December 19, 1988, Edward Neff
and Hale Biopharmaventures, LLC (each individually referred to herein as a “Guarantor” and collectively, the “Guarantors”). 
 RECITALS 
 A.       Borrower
proposes to obtain a credit line (the “Loan”) from UBS Bank USA (the “Bank”) pursuant to a Credit Line Agreement dated on or about the date hereof (as the same may be amended from time to time, the “Loan
Document”). 
 B.       As a condition to closing on the
transactions contemplated by the Loan Document, the Bank has required that the Guarantors guaranty the obligations of Borrower under the Loan Document pursuant to a Credit Line Guaranty Agreement (the “Guaranty”). 

C.       The Guarantors have agreed to enter into the Guaranty, provided Borrower enters
into this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, the Borrower and the Guarantors agree as follows: 

1.       REIMBURSEMENT OBLIGATION. 

1.1     Reimbursement Obligation.    If Bank enforces its rights under the
Guaranty (a “Drawing”) or if any Guarantor is otherwise obligated to pay to Bank any other amount under the Guaranty or to incur any expense in connection with a Drawing (collectively “Other Payments”), Borrower
shall reimburse such Guarantor by making (or causing to be made) to such Guarantor a payment in cash in the amount of such Drawing or Other Payment immediately on the date of the Drawing. 

1.2     Reimbursement Obligations Absolute.    The obligation of Borrower
to reimburse a Guarantor for Drawings or Other Payments shall be absolute, unconditional and irrevocable, and shall be performed strictly in accordance with the terms of this Agreement under and without regard to any circumstances, including
(a) any lack of validity or enforceability of the Loan Document, (b) any amendment or waiver or any consent to departure from all or any terms of the Loan Document, (c) the existence of any claim, set off, defense or other right that
Borrower may have at any time against the Bank or any transferee of the Guaranty, the Guarantors or any other person, whether in connection with this Agreement, the transactions contemplated herein, the Loan Document, or any unrelated transaction,
(d) any breach of contract or dispute between or among the Bank, Borrower, the Guarantors or any other person, (e) any non-application or misapplication of the proceeds of any Drawing, or
(f) any other circumstance or happening whatsoever, whether or not similar to any of the foregoing. 

2.       SECURITY INTEREST. 

  
 1 

 2.1     Security
Interest.    Borrower hereby grants and pledges to each Guarantor a continuing security interest in the property described on Exhibit A attached hereto to secure prompt repayment of any and all of Borrower’s
obligations to each Guarantor hereunder and to secure prompt performance by Borrower of each of its covenants and duties hereunder. At any time and from time to time Borrower shall execute and deliver such further instruments and take such further
action as may be requested by any Guarantor to effect the purposes of this Agreement and the security granted hereunder. 
 2.2     Remedies.    The Guarantors shall have all rights and may exercise any remedies available to them at law or in equity, successively or concurrently,
including without limitation any remedies available to them under the Uniform Commercial Code, as amended or supplemented from time to time. Borrower hereby irrevocably appoints the Guarantors as Borrower’s true and lawful attorney in fact,
such appointment, and each and every one of the Guarantors’ rights and powers, being coupled with an interest, is irrevocable until the Loan has been fully repaid. 
 3.       WARRANTS. 

3.1     Warrants.  Upon execution of this Agreement, Borrower shall deliver to each
Guarantor a duly executed Warrant to purchase shares of Borrower’s Common Stock, in substantially the form attached hereto as Exhibit B, where the “Warrant Coverage Amount” for each Guarantor’s Warrant shall be an amount equal to
50% of such Guarantor’s individual Guaranty. 
 4.       MISCELLANEOUS. 

4.1     Notices.    All notices required or permitted hereunder shall be
in writing (including facsimile, electronic mail or similar electronic transmissions), and shall be deemed effectively given: (a) when received by the addressee, if delivered by hand, facsimile, electronic mail or similar form of electronic
transmission, (b) five days after mailing, if mailed by registered or certified mail, return receipt requested, postage prepaid or (c) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with
written verification of receipt. All communications shall be sent (i) to Borrower at 5810 Nancy Ridge Drive, San Diego, California 92121, Attn: William Kachioff, Facsimile No: (858) 320-8261 or (ii) to the Guarantors at the
address shown on the signature page hereto, or at such other address as such party may designate by written notice to the other party. 
 4.2     Waivers; Amendments.    Any term, covenant, agreement or condition of this Agreement may be amended or waived if such amendment or waiver is in
writing and is signed by each Guarantor and Borrower. No failure or delay by the Guarantors in exercising any right hereunder shall operate as a waiver thereof or of any other right nor shall any single or partial exercise of any such right preclude
any other further exercise thereof or of any other right. Unless otherwise specified in such waiver or consent, a waiver or consent given hereunder shall be effective only in the specific instance and for the specific purpose for which given.

 4.3     Successors and Assigns.    This Agreement shall be
binding upon and inure to the benefit of Borrower, the Guarantors, and their respective successors and permitted assigns. However, in no event may Borrower assign or transfer any of his rights or obligations under this Agreement without the prior
written consent of each Guarantor. 

  
 2 

 4.4     Governing Law; Venue.  This
Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California without giving effect to its conflicts of
laws principles. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to
and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of San Diego, California. 
 4.5     Expenses.  Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement.

 4.6     Entire Agreement.    This Agreement constitutes the
entire agreement of the parties and supersedes any and all prior agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. 

4.7     Counterparts.    This Agreement may be executed in any number of
identical counterparts, any set of which signed by all the parties hereto shall be deemed to constitute a complete, executed original for all purposes. 

  
 3 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the day and
year first above written. 
  

			
	 BORROWER:
  

Biocept, Inc.,
 a California
corporation

	
	/s/ William G. Kachioff
	 William Kachioff

Chief Financial Officer

 GUARANTORS: 
 The Reiss Family Survivor’s Trust UDT dated December 19, 1988 
  

			
	By:	 	/s/ Claire K.T. Reiss
	Name:	 	Claire K.T. Reiss
	Title:	 	Trustee

 Edward Neff 
  

			
	By:	 	/s/ Edward Neff

  

			
	Hale Biopharmaventures, LLC
		
	By:	 	/s/ David F. Hale

			
	Name:	 	David F. Hale

			
	Title:	 	Chairman & CEO

  
 4 

 EXHIBIT A 

COLLATERAL 
 All of Borrower’s interest, whether presently existing or hereafter created or acquired, and wherever located, in the following (all of which being collectively referred to herein as the
“Collateral”): 
 (a)     All Accounts of Borrower; 

(b)     All Chattel Paper of Borrower; 

(c)     All Commodity Accounts of Borrower; 

(d)     All contracts of Borrower; 

(e)     All Deposit Accounts of Borrower; 

(f)     All Documents of Borrower; 

(g)     All General Intangibles of Borrower, including, without limitation, any intellectual
property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or received by Borrower or in which Borrower now holds or hereafter acquires or receives any right or interest; 

(h)     All Goods of Borrower, including, without limitation, Equipment, Inventory and
Fixtures; 
 (i)     All Instruments of Borrower, including, without limitation,
Promissory Notes; 
 (j)     All Investment Property of Borrower; 

(k)     All Letter-of Credit Rights of Borrower; 

(l)     All Money of Borrower; 

(m)     All Securities Accounts of Borrower; 

(n)     All Supporting Obligations of Borrower; 

(o)     All property of Borrower held by the Guarantors, or any other party for whom the
Guarantor are acting as agent, including, without limitation, all property of every-description now or hereafter in the possession or custody of or in transit to the Guarantors or such other party for any purpose, including, without limitation,
safekeeping, collection or pledge, for the account of Borrower, or as to which Borrower may have any right or power; 
 (p)     All other goods and personal property of Borrower, wherever located, whether tangible or intangible, and whether now owned or hereafter acquired, existing, leased or
consigned by or to Borrower; and 

  
 5 

 (q)     To the extent not otherwise included, all
Proceeds of each of the foregoing and all accessions to, substitutions and replacements for and rents, profits and products of each of the foregoing. 
 Notwithstanding the foregoing, the term “Collateral” shall not include: (a) the collateral which is subject to the security interest on certain assets of Borrower granted to Key Equipment
Finance Inc., (b) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or
otherwise or (c) any Account, Chattel Paper, General Intangible or Promissory Note in which Borrower has any right, title or interest if and to the extent such Account, Chattel Paper, General Intangible or Promissory Note includes a provision
containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Borrower therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person
party to such Account, Chattel Paper, General Intangible or Promissory Note to enforce any remedy with respect thereto; provided that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has
otherwise consented to the creation hereunder of a security interest in such Account, Chattel Paper, General Intangible or Promissory Note or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-406(d), 9-407(a) or
9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); provided further that immediately upon the ineffectiveness, lapse or
termination of any such provision, the Collateral shall include, and Borrower shall be deemed to have granted on the date hereof a security interest in, all its rights, title and interests in and to such Account, Chattel Paper, General Intangible or
Promissory Note as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect the Guarantors’ unconditional continuing security interest
in and to all rights, title and interests of Borrower in or to any payment obligations or other rights to receive monies due or to become due under any such Account, Chattel Paper, General Intangible or Promissory Note and in any such monies and
other proceeds of such Account, Chattel Paper, General Intangible or Promissory Note. 
 All terms above have the meanings given
to them in the Uniform Commercial Code as the same may from time to time be in effect in the State of California. 

  
 6 

 EXHIBIT B 

FORM OF WARRANT TO PURCHASE COMMON
STOCK 

  
 7EX-10.21.1

 Exhibit 10.21.1 
 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

BIOCEPT, INC. 
 WARRANT TO PURCHASE COMMON STOCK 
  

			
	No. CSW-[__] 	  	July [__], 2013

 THIS CERTIFIES THAT, for value
received, [                    ], or their assigns (collectively, the “Holder”), is entitled to subscribe for
and purchase at the Exercise Price (defined below) from BIOCEPT, INC., a California corporation (the “Company”), up to such number of fully paid and nonassessable shares of
Common Stock of the Company as set forth herein, during the Exercise Period (as defined below). 
 1.
DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 
 (a)
“Exercise Period” shall mean the period commencing on the date of the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933,
as amended, covering the offer and sale of the Company’s Common Stock for the account of the Company (the “IPO”) and ending two (2) years thereafter, unless sooner terminated as provided below. 

(b) “Exercise Price” shall mean the per share purchase price of the Company’s Common
Stock sold in the IPO. 
 (c) “Exercise Shares” shall mean the Company’s
Common Stock. 
 (d) “Warrant Coverage Amount” shall mean
$[                    ]. 
 2. NUMBER OF SHARES. The number of Exercise Shares for up to which this Warrant may be exercisable shall be determined by dividing the Warrant Coverage
Amount by the Exercise Price, and rounding down to the nearest whole share. 
 3. EXERCISE OF
WARRANT. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth on the signature page hereto (or at
such other address as it may designate by notice in writing to the Holder): 
 (a) An executed Notice of Exercise in the
form attached hereto; 

 (b) Payment of the Exercise Price either (i) in cash or by check, (ii) by
cancellation of indebtedness, or (iii) any combination thereof; and 
 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased,
registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised.

 The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that,
if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock
transfer books are open. 
 4. REPRESENTATIONS OF THE HOLDER.

 4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring this Warrant
and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial interests of
this Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

4.2 Information and Sophistication. Holder hereby: (i) acknowledges that it has received all the information it has requested
from the Company and it considers necessary or appropriate for deciding whether to acquire this Warrant and the Exercise Shares, (ii) represents that it has had an opportunity to ask questions and receive answers from the Company regarding the
financial condition of the Company and the risks associated with the acquisition of this Warrant and the Exercise Shares and (iii) further represents that it has such knowledge and experience in financial and business matters that it is capable
of evaluating the merits and risk of this investment. 
 4.3 Ability to Bear Economic Risk. Holder acknowledges that
investment in the securities of the Company involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Exercise Shares for an indefinite period of time and to suffer a complete
loss of its investment. 
 4.4 Securities Are Not Registered. 

(a) The Holder understands that this Warrant and the Exercise Shares have not been registered under the Securities Act on the
basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of
acquiring the securities for a fixed or determinable period in the future, selling (in 

  
 2. 

 
connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention. 

(b) The Holder recognizes that this Warrant and the Exercise Shares must be held indefinitely unless they are subsequently
registered under the Securities Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register this Warrant or the Exercise Shares, or to comply with any exemption from such
registration. 
 4.5 Disposition of Warrant and Exercise Shares. 

(a) The Holder further agrees not to make any disposition of all or any part of this Warrant or Exercise Shares in any event
unless and until: 
 (i) The Company shall have received a letter secured by the Holder from the Securities and Exchange
Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii) There is then in effect a registration statement under the Securities Act covering such proposed disposition and such
disposition is made in accordance with said registration statement; or 
 (iii) The Holder shall have notified the
Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company
with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of this Warrant or Exercise Shares under the Securities Act or any applicable state securities laws.
The Company agrees that it will not require an opinion of counsel with respect to transactions under Rule 144 of the Securities Act, except in unusual circumstances. 
 (b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following legend: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

  
 3 

 4.6 Accredited Investor Status. The Holder is an accredited investor or is
represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 
 5.
COVENANTS OF THE COMPANY. 
 5.1 Covenants as to Exercise
Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from
all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number
of shares to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares is not sufficient to permit exercise of this Warrant, the Company will take such
corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares to such number of shares as shall be sufficient for such purposes. 

5.2 No Impairment. Except and to the extent as waived or consented to by the Holder, the Company will not, by amendment of
its Amended and Restated Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in
order to protect the exercise rights of the Holder against impairment. 
 6. ADJUSTMENT OF
EXERCISE PRICE. In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations,
reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate
Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided,
however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 8 below. The form of this Warrant need not be changed because of any adjustment in
the number of Exercise Shares subject to this Warrant. 
 7. FRACTIONAL SHARES. No
fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

  
 4. 

 8. EARLY TERMINATION. In the event of,
at any time during the Exercise Period, any capital reorganization, or any reclassification of the capital stock of the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a
stock dividend or subdivision, split-up or combination of shares), or an Asset Transfer or Acquisition (as defined in the Company’s Amended and Restated Articles of Incorporation, as amended) (other than a merger solely to effect a
reincorporation of the Company into another state), the Company shall provide to the Holder 20 days advance written notice of such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and
this Warrant shall terminate unless exercised prior to the occurrence of such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets. 

9. MARKET STAND-OFF AGREEMENT. Holder shall not sell,
dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to, any Common Stock (or other securities) of the Company held
by such Holder, for a period of time specified by the managing underwriter(s) not to exceed 180 days following the effective date of a registration statement of the Company filed under the Securities Act in connection with the IPO (or such longer
period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation).
Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto. In order to
enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. Each Holder agrees that any transferee of Common Stock (or other securities)
shall be bound by this Section 9. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9 and shall have the right, power and authority to enforce the provisions hereof as though they were a
party hereto. 
 10. NO SHAREHOLDER RIGHTS. This Warrant in and of itself
shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company. 
 11.
TRANSFER OF WARRANT. Subject to applicable laws and the restrictions on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly
authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

12. LOST, STOLEN, MUTILATED OR DESTROYED
WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

  
 5. 

 13. NOTICES, ETC. All notices required or permitted
hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then
on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to the Company and the Holder at the address set forth on the signature page hereto, or at such other address as the Company or Holder may designate by 10 days advance
written notice to the other party hereto. 
 14. ACCEPTANCE. Receipt of this Warrant by the Holder shall
constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 15.
COUNTERPARTS. This Warrant may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

16. GOVERNING LAW. This Warrant shall be governed by, and construed and enforced in accordance with,
the laws of the State of California, applied to agreements between California residents, made to be performed entirely within the State of California, without giving effect to conflicts of law principles. 

17. AMENDMENT; WAIVER. Any term of this Warrant may be amended or waived with the written consent of
the Company and the Holder. 
 [REMAINDER OF THIS PAGE
INTENTIONALLY LEFT BLANK] 

  
 6. 

 IN WITNESS
WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of the date set forth above. 

 

			
	BIOCEPT, INC.
		
	By:	 	 

 
			
		
	Name:	 	 

 
			
		
	Title:	 	 

 
			
		
	Address:	 	 5810 Nancy Ridge Drive

San Diego, California 92121

 Acknowledged and accepted: 
 [                        ] 

 

			
	 
	  

		
	Address:	 	 
		 	 

  

[SIGNATURE PAGE TO WARRANT] 

 NOTICE OF EXERCISE 
 TO: BIOCEPT, INC. 
 (1) The undersigned
hereby elects to purchase              Exercise Shares of Biocept, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any. 
 (2) Please issue a
certificate or certificates representing said Exercise Shares in the name of the undersigned or in such other name as is specified below: 
  

 
 (Name)

  
  

 
  

(Address) 

(3) The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for the account of the undersigned
for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s
business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making
investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the
undersigned understands that the Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they
must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted
under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the
public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid Exercise Shares unless and until
there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of
counsel satisfactory to the Company, stating that such registration is not required. 
  

							
	 	 		 	 
	(Date)	 		 	(Signature)
			
		 		 	 
		 		 	(Print name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to 
  

			
	Name:	  	 
		  	(Please Print)
		
	Address: 	  	 
		  	(Please Print)

 Dated:
                    , 20__ 

Holder’s 

Signature:                       
                                         
                                         
         
 Holder’s 
 Address:                                
                                         
                                        

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]